Nanoparticles: Health effects - Pros and cons

Environmental Health Perspectives

Volumn 114, Issue 12, 2006, Pages 1818-1825

  Gwinn, Maureen R ^a   Vallyathan, Val ^a  

^a NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

Cons; Nanoparticle toxicity; Nanotechnology; Pros

Indexed keywords

ANTIBODY; CHITOSAN; DENDRIMER; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATIN; GOLD; IRON OXIDE; LIPOSOME; PHOSPHOLIPASE A2; POLYETHYLENE; POLYLYSINE; PROTEIN; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA;

CANCER THERAPY; CARDIOVASCULAR FUNCTION; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; DUST; ENGINEERING; ENVIRONMENTAL EXPOSURE; ETHICS; GENE THERAPY; HEALTH HAZARD; HUMAN; INDUSTRY; NANOPARTICLE; NANOTECHNOLOGY; NONHUMAN; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; RESPIRATORY FUNCTION; REVIEW; SURFACE PROPERTY; TOXICITY;

ENVIRONMENTAL HEALTH; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE;

EID: 33845346100     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.8871     Document Type: Review

References (90)

1. Allen TN, Cullis PR. 2004. Drug delivery systems: Entering the mainstream, Science 303:1818-1821.
2. 2 activation of lipposome-forming prodrugs. J Med Chem 47(7):1694-1703.
3. Antonini JM, Roberts JR, Jernigan MR, Yang HM, Me JY, Clarke RW. 2002. Residual oil fly ash increases the susceptibility to infection and severely damages the lungs after pulmonary challenge with a bacterial pathogen. Toxicol Sci 70(1): 110-119.
4. Aston A. 2005. Nanotech: BeamiHg In on Nano Gold. Available: http://www.businessweek.com/magazine/content/05_26/b3939624.htm [accessed 5 August 2006].
5. Batalha JR, Saldiva PH, Clarke RW, Coull BA, Stearns RC, Lawrence J, et al. 2002. Concentrated ambient air particles induce vasoconstriction of small pulmonary arteries in rats. Environ Health Perspect 110:1191-1197.
6. Bharali DJ, Klejbor I, Stachowiak EK, Dutta P, Roy I, Kaur N, et al. 2005. Organically modified silica nanoparticles: A nonviral vector for in vivo gene delivery and expression in the brain. Proc Natl Acad Sci USA 102(32):11539-11544.
7. Brook RD, Franklin B, Cascio W, Hong Y, Howard G, Lipsett M, et al. 2004. Air pollution and cardiovascular disease: A statement for healthcare professionals from the Expert Panel on Population and Prevention Science of the American Heart Association. Circulation 109(21):2655-2671.
8. Brown DM, Wilson MR, MacNee W, Stone V, Donaldson K. 2001. Size-dependent proinflammatory effects of ultrafine polystyrene particles: A role for surface area and oxidative stress in the enhanced activity of ultrafines. Toxicol Appl Pharmacol 175(3):191-199.
9. Brown JS, Zeman KL, Bennett WD. 2002. Ultrafine particle deposition and clearance in the healthy and obstructed lung. Am J Respir Crit Care Med 166(9):1240-1247.
10. Bruchez M Jr, Moronne M, Gin P, Weiss S, Alivisatos AP. 1998. Semiconductor nanocrystals as fluorescent biological labels. Science 281(5385):2013-2016.
11. Delfino RJ, Sioutas C, Malik S. 2005. Potential role of ultrafine particles in associations between airborne particle mass and cardiovascular health. Environ Health Perspect 113(8):934-946.
12. 11In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy. Clin Cancer Res 11(19 pt 2):7087s-7092s.
13. Dick CA, Brown DM, Donaldson K, Stone V. 2003. The role of free radicals in the toxic and inflammatory effects of four different ultrafine particle types. Inhal Toxicol 15(1):39-52.
14. Dockery DW, Luttmann-Gibson H, Rich DO, Link MS, Mittleman MA, Gold DR, et al. 2005. Association of air pollution with increased incidence of ventricular tachyarrhythmias recorded by implanted cardioverter defibrillators. Environ Health Perspect 113:670-674.
15. Dockery DW, Pope CA III, Xu X, Spengler JD, Ware JH, Fay ME, et al. 1993. An association between air pollution and mortality in six U.S. cities. N Engl J Med 329(24):1753-1759.
16. Dominici F, Peng RD, Bell ML, Pham L, McDermott A, Zeger SL, et al. 2006. Fine particulate air pollution and hospital admission for cardiovascular and respiratory diseases. JAMA 295(10):1127-1134.
17. Donaldson K, Gilmour PS, Borm P, Stone V. 2004a. Respiratory health effects of ambient air pollution particles. In: Oxygen Nitrogen Radicals (Vallyathan V, Castranova V, Shi X, eds). New York:MArcel Dekker, 257-288.
18. Donaldson K, Stone V, Tran CL, Kreyling W, Borm PJ. 2004b. Nanotoxicology. Occup Environ Med 61(9):727-728.
19. Donaldson K, Tran CL. 2002. Inflammation caused by particles and fibers. Inhal Toxicol 14(1):5-27.
20. Dufes C, Keith WN, Bilsland A, Proutski I, Uchegbu IF, Schatzlein AG. 2005. Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors. Cancer Res 65(18):8079-8084.
21. El-Sayed IH, Huang X, El-Sayed MA. 2006. Selective laser photothermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett 239(1): 129-135.
22. Elias PM, Tsai J, Menon GK, Holleran WM, Feingold KR. 2002. The potential of metabolic interventions to enhance transdermal drug delivery. J Investig Dermatol Symp Proc 7(1):79-85.
23. Gabizon A, Shmeeda H, Barenholz Y. 2003. Pharmacokinetics of pegylated liposomal Doxorubicin: Review of animal and human studies. Clin Pharmacokinet 42(5):419-436.
24. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. 2004. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 22(8):969-976.
25. Geiser M, Rothen-Rutishauser B, Kapp N, Schurch S, Kreyling W, Schulz H, efst al 2005. Ultrafine particles cross cellular membranes by nonphagocytic mechanisms in lungs and in cultured cells. Environ Health Perspect 113:1555-1560.
26. Gelperina S, Kisich K, Iseman MD, Heifets L. 2005. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med 172(12):1487-1490.
27. Gold DR, Litonjua AA, Schwartz J, Verrier M, Milstein R, Larson A, et al. 1998. Cardiovascular vulnerability to particulate pollution [Abstract]. Am J Respir Crit Care Mad 157:A261.
28. Gong H Jr, Linn WS, Clark KW, Anderson KR, Geller MD, Sioutas C. 2005. Respiratory responses to exposures with fine particulates and nitrogen dioxide in the elderly with and without COPD. Inhal Toxicol 17(3):123-132.
29. Gopalan B, Ito I, Branch CD, Stephens C, Roth JA, Ramesh R. 2004. Nanoparticle based systemic gene therapy for lung cancer: Molecular mechanisms and strategies to suppress nanoparticle-mediated inflammatory response. Technol Cancer Res Treat 3(6):647-657.
30. Hinds WC. 1999. Aerosol Technology: Properties, Behavior, and Measurement of Airborne Particles, 2nd ed. New York:WIley-Interscience.
31. Hoet PH, Bruske-Hohlfeld I, Salata OV. 2004. Nanoparticles - known and unknown health risks. J Nanobiotechnology 2(1):12.
32. Kaul G, Amiji M. 2005. Tumor-targeted gene delivery using poly(ethylene glycol)-modified gelatin nanoparticles: In vitro and in vivo studies. Pharm Res 22(6):951-961.
33. Koenig JO, Mar TF, Allen RW, Jansen K, Lumley T, Sullivan JH, et al. 2005. Pulmonary effects of indoor- and outdoor-generated particles in children with asthma. Environ Health Perspect 113:499-503.
34. Kreyling WG, Semmler M, Erbe F, Mayer P, Takenaka S, Schulz H, et al. 2002. Translocation of ultrafine insoluble iridium particles from lung epithelium to extrapulmonary organs is size dependent but very low. J Toxicol Environ Health A 65(20): 1513-1530.
35. Kumar MN, Mohapatra SS, Kong X, Jena PK, Bakowsky U, Lehr CM. 2004. Cationic poly(lactide-co-glycolide) nanoparticles as efficient in vivo gene transfection agents. J Nanosci Nanotechnol 4(8):990-994.
36. Lademann J, Weigmann H, Rickmeyer C, Barthelmes H, Schaefer H, Mueller G, et al. 1999. Penetration of titanium dioxide microparticles in a sunscreen formulation into the horny layer and the follicular orifice. Skin Pharmacol Appl Skin Physiol 12(5):247-256.
37. Lam CW, James JT, McCloskey R, Hunter RL. 2004. Pulmonary toxicity of single-wall carbon nanotubes in mice 7 and 90 days after intratracheal instillation. Toxicol Sci 77(1):126-134.
38. Li Z, Carter JD, Dailey LA, Huang YC. 2005a. Pollutant particles produce vasoconstriction and enhance MAPK signaling via angiotensin type 1 receptor. Environ Health Perspect 113: 1009-1014.
39. Li Z, Zhu S, Gap K, Zhang Q, Zeng Z, Zhou Y, et al. 2005b. Poly-L-lysine-modified silica nanoparticles: A potential oral gene delivery system. J Nanosci Nanotechnol 5(8):1199-1203.
40. Mansouri S, Cuie Y, Winnik F, Shi Q, Lavigne P, Benderdour M, et al. 2006. Characterization of folate-chitosan-DNA nanoparticles for gene therapy. Biomaterials 27(9):2060-2065.
41. Menon GK, Elias PM. 1997. Morphologic basis for a pore-pathway in mammalian stratum corneum. Skin Pharmacol 10(5-6): 235-246.
42. Menon GK, Kollias N, Doukas AG. 2003. Ultrastructural evidence of stratum corneum permeabilization induced by photomechanical waves. J Invest Dermatol 121(1):104-109.
43. Mills NL, Amin N, Robinson SD, Anand A, Davies J, Patel D, et al. 2006. Do inhaled carbon nanoparticles translocate directly into the circulation in humans? Am J Respir Crit Care Med 173(4):426-431.
44. Moghimi SM, Hunter AC, Murray JC. 2005. Nanomedicine: Current status and future prospects. Faseb J 19(3):311-330.
45. National Nanotechnology Initiative. 2005. What is Nanotechnology? Available: http://www.nano.gov/html/facts/whatIsNano.html [accessed 10 November 2005].
46. Nel A. 2005. Atmosphere. Air pollution-related illness: Effects of particles. Science 308(5723):804-806.
47. Nel A, Xia T, Madler L, Li N. 2006. Toxic potential of materials at the nanolevel. Science 311(5761):622-627.
48. Nemmar A, Hoet PH, Vanquickenborne B, Dinsdale D, Thomeer M, Hoylaerts MF, et al. 2002a. Passage of inhaled particles into the blood circulation in humans. Circulation 105(4):411-414.
49. Nemmar A, Hoylaerts MF, Hoet PH, Dinsdale O, Smith T, Xu H, et al. 2002b. Ultrafine particles affect experimental thrombosis in an in vivo hamster model. Am J Respir Crit Care Med 166(7):998-1004.
50. Nemmar A, Hoylaerts MF, Hoet PH, Vermylen J, Nemery B. 2003. Size effect of intratracheally instilled particles on pulmonary inflammation and vascular thrombosis. Toxicol Appl Pharmacol 186(1):38-45.
51. Niemeyer CM. 2001. Nanoparticles, proteins, and nucleic acids: biotechnology meets material science. Agnew Chem Int Ed Engl 40:4128-4158.
52. Nurkiewicz TR, Porter DW, Barger M, Castranova V, Boegehold MA. 2004. Particulate matter exposure impairs systemic microvascular endothelium-dependent dilation. Environ Health Perspect 112(13):1299-1306.
53. O'Neal DP, Hirsch LR, Halas NJ, Payne JD, West JL. 2004. Photothermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett 209(2):171-176.
54. Oberdörster G. 2001. Pulmonary effects of inhaled ultrafine particles. Int Arch Occup Environ Health 74(1):1-8.
55. Oberdörster G, Ferin J, Lehnert BE. 1994. Correlation between particle size, in vivo particle persistence, and lung injury. Environ Health Perspect 102(suppl 5):173-179.
56. Oberdörster G, Gelein RM, Ferin J, Weiss B. 1995. Association of particulate air pollution and acute mortality: Involvement of ultrafine particles? Inhal Toxicol 7(1):111-124.
57. Oberdörster G, Maynard A, Donaldson K, Castranova V, Fitzpatrick J, Ausman K, et al. 2005a. Principles for characterizing the potential human health effects from exposure to nanomaterials: Elements of a screening strategy. Part Fibre Toxicol 2(1):1-60.
58. Oberdörster G, Oberdörster E, Oberdörster J. 2005b. Nanotoxicology: An emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 113:823-839.
59. Oberdorster G, Sharp Z, Atudorei V, Elder A, Gelein R, Keyling W, et al. 2004. Translocation of inhaled ultrafine particles to the brain. Inhal Toxicol 16:437-445.
60. Oberdörster G, Sharp Z, Atudorei V, Elder A, Gelein R, Lunts A, at al. 2002. Extrapulmonary translocation of ultrafine carbon particles following whole-body inhalation exposure of rats. J Toxicol Environ Health A 65(20):1531-1543.
61. Oberdörster G, Utell MJ. 2002. Ultrafine particles in the urban air: to the respiratory tract - and beyond? [Editorial]. Environ Health Perspect 110:A440-A441.
62. Park SK, O'Neill MS, Vokonas PS, Sparrow D, Schwartz J. 2005. Effects of air pollution on heart rate variability: The VA normative aging study. Environ Health Perspect 113:304-309.
63. Perkel JM. 2004. The ups and downs of nanobiotech. The Scientist 18(16):14-18.
64. Peters A, Dockery DW, Muller JE, Mittleman MA. 2001. Increased particulate air pollution and the triggering of myocardial infarction. Circulation 103(23):2810-2815.
65. Peters A, Doring A, Wichmann HE, Koenig W. 1997. Increased plasma viscosity during an air pollution episode: A link to mortality? Lancet 349(9065):1582-1587.
66. Peters A, Liu E, Verrier RL, Schwartz J, Gold DR, Mittleman M, at al. 2000. Air pollution and incidence of cardiac arrhythmia. Epidemiology 11(1):11-17.
67. Pietropaoli AP, Frampton MW, Hyde RW, Morrow PE, Oberdörster G, Cox C, et al. 2004. Pulmonary function, diffusing capacity, and inflammation in healthy and asthmatic subjects exposed to ultrafine particles. Inhal Toxicol 16 (suppl 1):59-72.
68. Pope CA III, Burnett RT, Thurston GD, Thun MJ, Calle EE, Krewski D, et al. 2004 Cardiovascular mortality and long-term exposure to particulate air pollution: Epidemiological evidence of general pathophysiological pathways of disease. Circulation 109(1):71-77.
69. Pope CA III, Thun MJ, Namboodiri MM, Dockery DW, Evans JS, Speizer FE, et al. 1995. Particulate air pollution as a predictor of mortality in a prospective study of U.S. adults. Am J Respir Crit Care Med 151(3 pt 1):669-674.
70. Pope CA, Dockery DW, Kanner RE, Villegas GM, Schwartz J. 1999. Oxygen saturation, pulse rate, and particulate air pollution: A daily time-series panel study. Am J Respir Crit Care Med 159(2):365-372.
71. Prabha S, Labhasetwar V. 2004. Nanoparticle-mediated wild-type p53 gene delivery results in sustained antiproliferative activity in breast cancer cells. Mol Pharm 1(3):211-219.
72. Prahalad AK, Soukup JM, Inmon J, Willis R, Ghio AJ, Becker S, et al. 1999. Ambient air particles: Effects on cellular oxidant radical generation in relation to particulate elemental chemistry. Toxicol Appl Pharmacol 158(2):81-91.
73. Renwick LC, Brown D, Clouter A, Donaldson K. 2004. Increased inflammation and altered macrophage chemotactic responses caused by two ultrafine particle types. Occup Environ Med 61(5):442-A47.
74. Roberts ES, Richards JH, Jaskot R, Dreher KL. 2003. Oxidative stress mediates air pollution particle-induced acute lung injury and molecular pathology. Inhal Toxicol 15(13):1327-1346.
75. Roco MC. 2005. Environmentally responsible development of nanotechnology. Environ Sci Technol 39(5):106A-112A.
76. Saldiva PH, Clarke RW, Coull BA, Stearns RC, Lawrence J, Murthy GG, et al. 2002. Lung inflammation induced by concentrated ambient air particles is related to particle composition. Am J Respir Crit Care Med 165(12):1610-1617.
77. Samet JM, Dominici F, Curriero FC, Coursac I, Zeger SL. 2000. Fine particulate air pollution and mortality in 20 U.S. cities, 1987-1994. N Engl J Med 343(24):1742-1749.
78. 2.5 and daily deaths. Environ Health Perspect 110:1025-1029.
79. Seaton A, MacNee W, Donaldson K, Godden D. 1995. Particulate air pollution and acute health effects. Lancet 345(8943): 176-178.
80. Shvedova AA, Kisin ER, Mercer R, Murray AR, Johnson VJ, Potapovich AI, et al. 2005. Unusual inflammatory and fibrogenic pulmonary responses to single-walled carbon nanotubes in mice. Am J Physiol Lung Cell Mol Physiol 289(5):L698-L708.
81. Shy C, Craison J, Williams R, Zweindinger R. 1998. Cardiovascular responses of elderly persons to particulate air pollution [Abstract]. Epidemiology 9:S77.
82. Silkoff PE, Zhang L, Dutton S, Langmack EL, Vedal S, Murphy J, et al. 2005. Winter air pollution and disease parameters in advanced chronic obstructive pulmonary disease panels residing in Denver, Colorado. J Allergy Clin Immunol 115(2):337-344.
83. Stoeger T, Reinhard C, Takenaka S, Schroeppel A, Karg E, Ritter B, et al. 2006. Instillation of six different ultrafine carbon particles indicates a surface area threshold dose for acute lung inflammation in mice. Environ Health Perspect 114:328-333.
84. Sun O, Wang A, Jin X, Natanzon A, Duquaine D, Brook RD, et al. 2005. Long-term air pollution exposure and acceleration of atherosclerosis and vascular inflammation in an animal model. JAMA 294(23):3003-3010.
85. Tinkle SS, Antonini JM, Rich BA, Roberts JR, Salmen R, DePree, et al. 2003. Skin as a route of exposure and sensitization in chronic beryllium disease. Environ Health Perspect 111:1202-1208.
86. U.S. Environmental Protection Agency. 2004. Air Quality Criteria for Particulate Matter. Available: http://cfpub.epa.gov/ncea/cfm/ partmatt.cfm [accessed 23 March 2006].
87. Warheit DB, Laurence BR, Reed KL, Roach DH, Reynolds GA, Webb TR. 2004. Comparative pulmonary toxicity assessment of single-wall carbon nanotubes in rats. Toxicol Sci 77(1):117-125.
88. Wellenius GA, Coull BA, Godleski JJ, Koutrakis P, Okabe K, Savage ST, et al. 2003. Inhalation of concentrated ambient air particles exacerbates myocardial ischemia in conscious dogs. Environ Health Perspect 111:402-408.
89. Wu X, Liu H, Liu J, Haley KN, Treadway JA, Larson JP, et al. 2003. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol 21(1):41-46.
90. Zhang Y, Kohler N, Zhang M. 2002. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials 23(7):1553-1561.